Pharvaris NV (PHVS)

PHVS Rare Disease

BiotechSign Signal Grade

D
Signal Grade
39.2/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Pdufa Date
15
Insider Buying
0
Publications
5
Dilution Risk
34
Clinical Activity
100
Short Interest
30
FDA PDUFA Target Date:2027-04-23 Source

Pipeline Overview

Therapeutic Focus
Rare Diseasesrc

Clinical Trial Activity

5
Clinical Trials
(ClinicalTrials.gov aggregate)
1 Phase 2, 5 Phase 3
Trial Phase Breakdown
1
PubMed Publication
1
Catalyst Record

ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov

Dilution Risk

MEDIUM DILUTION RISK
34/100
Dilution Score
40Warrant Risk
40Convertible Risk
42Offering Ability

Dilution score: 34/100 (MEDIUM), cash runway not available

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

5.01%
Float Shorted
2.8
Days to Cover
LOW
Squeeze Risk
+12.5%
SI Change
INCREASING
Trend
2,007,998
Shares Short

Short interest: 5.01% of float, squeeze risk: LOW

FINRA short sale data. FINRA short interest

Upcoming Catalysts

Recent News & SEC Filings

Headlines from public sources. BiotechSign does not endorse or verify linked content.

Recent Publications

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Pharvaris NV.

Full PHVS Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.